Contineum Therapeutics adopts amended charter and bylaws upon IPO closing

Contineum Therapeutics, Inc.

Authorized 200M Class A common and 20M Class B common shares, plus 10M undesignated preferred.
Classified board with staggered three-year terms; directors removable only for cause with 66 2/3% vote.
Exclusive forum: Delaware Chancery for derivative/breach claims; federal courts for Securities Act claims.
Stockholders cannot act by written consent or call special meetings; new procedures for proposals and nominations.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Contineum Therapeutics, Inc.: Adopted amended and restated bylaws effective upon IPO closing, eliminating stockholder action by written consent and establishing procedures for stockholder proposals and director nominations (effective 2024-04-09).

Change: bylaw amendment
Effective: 2024-04-09

Exact text from the filing

Effective as of April 9, 2024 the Company adopted amended and restated bylaws (the “Restated Bylaws”) in connection with the closing of the IPO.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Contineum Therapeutics, Inc.: Amended and restated certificate of incorporation in connection with IPO, including changes to authorized stock, board classification, and exclusive forum provisions (effective 2024-04-09).

Change: charter amendment
Effective: 2024-04-09

Exact text from the filing

On April 9, 2024, Contineum Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering (the “IPO”).

View on SEC.gov

261 governance changes filed in the last 30 days. Browse all governance changes →

Contineum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-090917

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.